Abstract: A high temperature-stable and highly purified ?-? cross-linked tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells obtained from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents the lysis of white blood cells. Nucleic acids from white blood cells and the phospholipids impurities are not detected. The blocking of reactive sulfhydryl groups in hemoglobin by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography is used to remove different plasma protein impurities. N-acetyl cysteine is added to the ?-? cross-linked tetrameric hemoglobin solution to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion.
Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
Type:
Grant
Filed:
July 18, 2008
Date of Patent:
June 3, 2014
Assignee:
Universite Paris-Sud XI
Inventors:
Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
Abstract: An objective of the invention is to provide an adsorbent allowing purification of a blood coagulation factor or a cell adhesion factor under mild conditions, according to simple procedures, and at a low cost and safely while having a high affinity and a high resistance to deterioration, and a method for purifying the blood coagulation factor or the cell adhesion factor; a solution is to apply a polypeptide having peptide fragments represented by formula (1) as the adsorbent for the blood coagulation factor or the cell adhesion factor, and to purify the blood coagulation factor or the cell adhesion factor using the adsorbent: -(Pro-Hyp-Gly)n- Wherein, in formula (1), n is an integer from 2 to 9,000.
Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
Type:
Grant
Filed:
October 2, 2009
Date of Patent:
May 6, 2014
Assignee:
Celtaxsys, Inc.
Inventors:
Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
Type:
Grant
Filed:
April 27, 2012
Date of Patent:
May 6, 2014
Assignee:
DYAX Corp.
Inventors:
Henry Blair, Thomas Beck, Robert C. Ladner
Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
Abstract: The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble Fc?R; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble Fc?R for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient.
Type:
Application
Filed:
October 30, 2012
Publication date:
May 1, 2014
Applicant:
SuppreMol GmbH
Inventors:
Peter Buckel, Peter Sondermann, Sascha Tillmanns, Ingrid Berger
Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
April 22, 2014
Assignee:
CMS Peptides Patent Holding Company Limited
Abstract: The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
April 22, 2014
Assignee:
Novo Nordisk Healthcare AG
Inventors:
Anne Charlotte Arentsen, Per Kaersgaard
Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 4 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to agonize or to antagonize GPCR receptors such as CXCR3, urotensin and CCR10. They can be used as medicaments to treat or prevent diseases such as cardiovascular disorders, dermatological disorders, endocrine system and hormone disorders, metabolic diseases, inflammatory diseases, neurological diseases, respiratory diseases, haematological diseases and cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
Type:
Application
Filed:
December 19, 2013
Publication date:
April 17, 2014
Applicant:
POLYPHOR LTD.
Inventors:
Daniel Obrecht, Frank Gombert, Steven J. Demarco, Christian Ludin, Alexander Lederer, Christian Bisang, Odile Sellier-Kessler, Francoise Jung, Reshmi Mukherjee, Heiko Henze, Barbara Romagnoli
Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.
Abstract: The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1?, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.
Type:
Application
Filed:
December 13, 2012
Publication date:
April 17, 2014
Inventors:
Bing Lou WONG, Norman Fung Man WAI, Sui Yi KWOK, Sze Hang LAU
Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 27, 2014
Inventors:
Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
Abstract: The present invention describe nanocomplexes also called auto-assembling nanoparticles comprising biphosphonates, lipid nanovectors and inorganic nanovectors. In particular the invention describes zoledronic acid complexed with calcium phosphate base nanoparticles; said particles in their turn mixed with lipidic particles e.g. liposomes. Said nanocomplexes are useful, and showed to be efficient in vivo, as pharmaceutical formulations of biphosphonates for the treatment or prevention of tumor growth and/or metastasis. Tumors can be solids and/or haematological such as prostate, lung, head/neck, colon, liver, breast, pancreas, kidneys, bladder, male and female urogenital tract, bones, multiple myeloma, primitive and secondary tumours of the central nervous system and lymphomas.
Abstract: The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by evaluating the healing of tympanic membrane perforations in an animal model.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
March 25, 2014
Assignee:
Omnio Healer AB
Inventors:
Tor Ny, Jinan Li, Sten Hellstrom, Per-Olof Eriksson
Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
Type:
Grant
Filed:
May 18, 2013
Date of Patent:
March 25, 2014
Assignee:
Moderna Therapeutics, Inc.
Inventors:
Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
Type:
Application
Filed:
October 1, 2013
Publication date:
March 13, 2014
Applicants:
MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body Corporate
Inventors:
Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
Abstract: The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.
Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
February 25, 2014
Assignee:
CMS Peptides Patent Holding Company Limited
Abstract: The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for a method the severe complication in hemolytic diseases comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles.
Abstract: A thiol-yne polymeric material and methods for producing said polymers are disclosed. The material is produced by the radically mediated polymerization of monomers having alkyne and thiol functional groups. The alkyne moiety, internal or terminal, may react with one or two thiols. Degradable monomers may be used to form degradable polymers.
Type:
Application
Filed:
January 27, 2012
Publication date:
February 6, 2014
Applicant:
The Regents of the University of Colorado, A Body Corporate
Inventors:
Kristi Anseth, Ben Fairbanks, Christopher Bowman
Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
Abstract: The present invention provides a genetic method of tethering polypeptides to the yeast cell wall in a form accessible for binding to macromolecules. Combining this method with fluorescence-activated cell sorting provides a means of selecting proteins with increased or decreased affinity for another molecule, altered specificity, or conditional binding. As one embodiment, attaching an scFv antibody fragment to the Aga2p agglutinin effectively mimics the cell surface display of antibodies by B cells in the immune system for affinity maturation in vivo. As another embodiment, T cell receptor mutants can be isolated by this method that are efficiently displayed on the yeast cell surface, providing a means of altering T cell receptor binding affinity and specificity by library screening.
Type:
Application
Filed:
February 12, 2013
Publication date:
January 30, 2014
Inventors:
K. Dane WITTRUP, David M. KRANZ, Michele KIEKE, Eric T. BODER
Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
Abstract: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.
Type:
Grant
Filed:
April 4, 2007
Date of Patent:
January 21, 2014
Assignees:
Regents of the University of Minnesota, The United States of America as represented by Department of Veterens Affairs
Inventors:
Gary L. Nelsestuen, Ronald Bach, Matthew Stone, Stephen Barrett Harvey
Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
Type:
Application
Filed:
June 21, 2013
Publication date:
January 9, 2014
Inventors:
Abraham ABUCHOWSKI, Glenn KAZO, Friedericke KAZO
Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
Abstract: The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor.
Type:
Grant
Filed:
April 9, 2008
Date of Patent:
December 31, 2013
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Scott Thomas Brady, Gerardo Andres Morfini
Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
Abstract: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
December 17, 2013
Assignees:
The University of North Carolina at Chapel Hill, Entegrion, Inc.
Inventors:
Thomas H. Fischer, E. Stan Eskridge, Jr., William M. Malloy, Jr., Malloy Evans
Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.
Type:
Grant
Filed:
May 27, 2010
Date of Patent:
December 17, 2013
Assignee:
GlaxoSmithKline LLC
Inventors:
Connie L. Erickson-Miller, Julian Jenkins
Abstract: This invention relates to the specific Asp76Asn (D76N) variant ?2-microglobulin (?2M) protein, nucleic acids encoding the same, their characterization and applications in studying amyloid fibrillogenesis, including diagnostic and therapeutic applications.
Type:
Application
Filed:
June 8, 2012
Publication date:
December 12, 2013
Inventors:
Vittorio Bellotti, Sophie Valleix, Mark Brian Pepys, Madeleine M. Riès-Kautt
Abstract: A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes.
Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
Type:
Grant
Filed:
June 11, 2012
Date of Patent:
November 19, 2013
Assignees:
Genexine, Inc., Postech Academy-Industry Foundation
Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
Type:
Grant
Filed:
July 21, 2006
Date of Patent:
November 19, 2013
Assignee:
CMS Peptides Patent Holding Company Limited
Abstract: The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, peri- or post-operative bleeding. A novel treatment is proposed in which synergistic pro-coagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited.
Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.
Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
Type:
Application
Filed:
March 11, 2013
Publication date:
October 17, 2013
Inventors:
Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
Abstract: Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like.
Type:
Application
Filed:
November 15, 2012
Publication date:
October 10, 2013
Applicant:
Industry-University Cooperation Foundation Hanyang University
Abstract: A process for the manufacture of a collagenous material from a plurality of collagen particles is described. The collagen particles are derived from a natural tissue material, are substantially free of non-fibrous tissue proteins, cellular elements and lipids or lipid residues, and comprise fragments of collagen fibres displaying original collagen fibre architecture and molecular ultrastructure of the natural tissue material. The process comprises the step of freeze drying the collagen particles in suspension in a freeze-drying suspension medium.
Type:
Application
Filed:
July 21, 2011
Publication date:
October 10, 2013
Applicant:
TISSUE SCIENCE LABORATORIES LIMITED
Inventors:
Paul Armitage, Christine Elizabeth Dawson
Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.
Type:
Application
Filed:
March 12, 2013
Publication date:
October 3, 2013
Applicants:
The Regents of the University of California, Albert Einstein College of Medicine of Yeshiva University
Inventors:
Seetharama A. Acharya, Marcos Intaglietta
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Type:
Application
Filed:
November 1, 2012
Publication date:
September 19, 2013
Applicant:
AFFYMAX, INC.
Inventors:
Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Application
Filed:
October 17, 2012
Publication date:
September 19, 2013
Applicant:
ACCELERON PHARMA, INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
Abstract: Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same.
Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Type:
Grant
Filed:
July 6, 2011
Date of Patent:
September 10, 2013
Assignees:
Carnell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon University
Inventors:
Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Type:
Grant
Filed:
April 17, 2008
Date of Patent:
September 10, 2013
Assignees:
Carnell Therapeutics Corporation, Carnegie Mellon University, Allegheny-Singer Research Institute
Inventors:
Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Type:
Grant
Filed:
July 6, 2011
Date of Patent:
September 10, 2013
Assignees:
Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon University
Inventors:
Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith